GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
GentiBio has raised $157.0M in total funding. The most recent round was Series A. The last funding was announced in August 2021.
GentiBio's investors include RA Capital Management, OrbiMed, Avidity Partners, Novartis Venture Fund, Seattle Children’s.
GentiBio is headquartered in Seattle, United States.
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
GentiBio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GentiBio — Funding & Investors." VCBacked, August 11, 2021, https://www.vcbacked.co/company/gentibio. Accessed August 13, 2026.
VCBacked. (2021). GentiBio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/gentibio
{{cite web |title=GentiBio — Funding & Investors |url=https://www.vcbacked.co/company/gentibio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated